Ibutamoren Dosage in 2026: What Clinicians Actually Prescribe

Ibutamoren at a glance:

• Drug class: Growth hormone secretagogue
• Route: subcutaneous injection (peptides) or oral (small molecules)
• Typical frequency: once daily to once weekly depending on agent
• Half-life: varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)

The wrong Ibutamoren dose — too high, too low, or escalated too quickly — is the most common reason people stop the drug. FDA-approved agents have specific labeled dosing.

Standard Dosing Schedule for Ibutamoren

FDA-approved agents have specific labeled dosing. Research-only GHS peptides have no validated human dosing.

The typical schedule for Ibutamoren is once daily to once weekly depending on agent via subcutaneous injection (peptides) or oral (small molecules). Half-life of varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677) explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for Ibutamoren holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of Ibutamoren is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in Ibutamoren side effects and the cost angle of dose escalation in Ibutamoren cost.

What the Trials Used

Published trial data for Ibutamoren comes primarily from: Stanley 2010 (tesamorelin in HIV-lipodystrophy); Nass 2008 (MK-677 in older adults).

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For Ibutamoren: the standard contraindications for this drug class apply.

Bottom Line

Most Ibutamoren dose questions resolve in a 5-minute conversation with a clinician. Don't carry them around — get them answered.

Frequently Asked Questions

Related Reading

• Ibutamoren: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• Ibutamoren Side Effects Decoded: What's Normal vs. What Isn't
• What Results Should You Expect from Ibutamoren? A Practical Guide
• The Real Ibutamoren Price Tag in 2026 — With and Without Insurance
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.